| http://www.w3.org/ns/prov#value | - r EU approval to treat adults with rare blood cancer polycythemia vera Polycythemia vera (PV) is associated with overproduction of blood cells that can cause serious cardiovascular complications, such as stroke and heart attack Clinical data show Jakavi (ruxol Medicine/Pharmacology21.01.2015 Novartis announces FDA approval for first IL-17A antagonist Cosentyx(TM) (secukinumab) for moderate-to-seve
|
